ArticleAdvances in therapy2025
Prevalence, Treatment Patterns, and Characteristics of US Adults with Confirmed or at Risk for Growth Hormone Deficiency.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results.The Journal of clinical endocrinology and metabolism · 2026Trial
- Population pharmacokinetics/pharmacodynamics and safety of YPEG-rhGH in elderly subjects.Frontiers in pharmacology · 2025Trial
- Article
- First 100 patients receiving long-acting growth hormone therapy: real-world evaluation from INSIGHTS-GHT registry.Orphanet journal of rare diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAdult growth hormone deficiency (GHD) is an endocrine disorder associated with increased morbidity and poor quality of life. The purpose of this study was to describe the clinical characteristics, treatment patterns, and prevalence of individuals at risk for adult GHD and individuals with confirmed adult GHD in the United States (US).
methodsUsing Veradigm Network electronic health records linked to claims, this study identified adults with a high likelihood of adult GHD based on having ≥ 1 of the following between January 1, 2017 and December 31, 2021: diagnosis of hypopituitarism or ≥ 1 related condition, such as Cushing disease, ≥ 3 pituitary hormone deficiencies other than GHD, ≥ 3 pituitary hormone treatments other than growth hormone (GH), or ≥ 1 prescription for GH. Index date was the earliest qualifying event. Individuals were stratified by GH level on or before index date: confirmed adult GHD (< 3 ng/mL), at risk for adult GHD (no test result), ruled-out (≥ 3 ng/mL).
resultsUS prevalence of adult GHD was estimated to be between 0.2 (confirmed) and 37.0 (confirmed + at-risk) per 100,000. Among 268 individuals with confirmed adult GHD and 54,310 at risk for adult GHD, mean age was 50 years old, and a majority were female. GH treatment was initiated in 9.7% of confirmed individuals and 3.1% of those at risk for adult GHD. Among confirmed and at-risk individuals, prevalence of endocrine-related conditions was higher in treated individuals, whereas prevalence of several metabolic and cardiovascular comorbidities was higher in those untreated. Only 32.2% of individuals who initiated treatment during the follow-up period were persistent until the end of follow-up.
conclusionsOur findings report US prevalence of adult GHD and suggest that adult GHD is commonly underdiagnosed in the US. Factors contributing to low rates of adult GHD diagnosis and treatment warrant further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.